Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "NOD2" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Nucleotide-binding oligomerization domain-containing protein 2 (NOD2), also known as caspase recruitment domain-containing protein 15 (CARD15) or inflammatory bowel disease protein 1 (IBD1), is a protein that in humans is encoded by the NOD2 gene located on chromosome 16. NOD2 plays an important role in the immune system. It recognizes bacterial molecules (peptidoglycans) and stimulates an immune reaction .
Nod2 nucleic acids and proteins
InactiveUS6858391B2Sugar derivativesMicrobiological testing/measurementIntracellular signallingNucleotide
The present invention relates to intracellular signalling molecules, in particular the Nod2 protein and nucleic acids encoding the Nod2 protein. The present invention provides isolated nucleotide sequence encoding Nod2, isolated Nod2 peptides, antibodies that specifically bind Nod2, methods for the detection of Nod2, and methods for screening compounds for the ability to alter Nod2 associated signal transduction. The present invention also provides Nod2 variant alleles. The present invention further provides methods of identifying individuals at increased risk of developing Crohn's disease.
Owner:RGT UNIV OF MICHIGAN +1
Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
ActiveUS8188058B2Reduce marksReduce signalingAntibacterial agentsBiocideDiseaseNK1 receptor antagonist
Owner:UNIVERSITY OF PITTSBURGH
Mutations in nod2 are associated with fibrostenosing disease in patients with crohn's disease
ActiveUS20070072180A1Sugar derivativesMicrobiological testing/measurementCrohn's diseaseSmall intestine
Owner:CEDARS SINAI MEDICAL CENT
Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
The present invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease characterized by fibrostenosing disease by determining the presence or absence in an individual of a fibrostenosis-predisposing allele linked to a NOD2 / CARD15 locus, where the presence of the fibrostenosis-predisposing allele is diagnostic of or predictive of susceptibility to the clinical subtype of Crohn's disease characterized by fibrostenosing disease. In a method of the invention, the clinical subtype of Crohn's disease can be, for example, characterized by fibrostenosing disease independent of small bowel involvement. The invention also provides a method of optimizing therapy in an individual by determining the presence or absence in the individual of a fibrostenosis-predisposing allele linked to a NOD2 / CARD15 locus, diagnosing individuals in which the fibrostenosis-predisposing allele is present as having a fibrostenosing subtype of Crohn's disease, and treating the individual having a fibrostenosing subtype of Crohn's disease based on the diagnosis.
Owner:CEDARS SINAI MEDICAL CENT
Nod2 nucleic acids and proteins
Owner:RGT UNIV OF MICHIGAN
Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
ActiveUS20080311112A1Reduce marksReduce signalingAntibacterial agentsBiocideDiseaseNK1 receptor antagonist
The present invention relates to the use of a TLR9 agonist and / or a TLR4 antagonist and / or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.
Owner:UNIVERSITY OF PITTSBURGH
Diagnosis and treatment of inflammatory bowel disease
This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and / or subtypes of Crohn's disease (CD) and / or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and / or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and / or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and / or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and / or treatment of IBD, including CD and / or UC.
Owner:CEDARS SINAI MEDICAL CENT
Methods of assessing crohn's disease patient phenotype by i2 serologic response
InactiveUS20100240077A1Microbiological testing/measurementDisease diagnosisCrohn's diseaseUlcerative colitis
Owner:CEDARS SINAI MEDICAL CENT
Methods of assessing Crohn's disease patient phenotype by I2 serologic response
ActiveUS7662569B2Predict susceptibilityMicrobiological testing/measurementDisease diagnosisCrohn's diseaseUlcerative colitis
The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti-Saccharomyces cerevisiae antibodies (ASCA), IgA anti-OmpC antibodies, or perinuclear anti-neutrophil cytoplasmic antibodies (pANCA). The methods of the invention can be used to diagnose or predict susceptibility to a clinical subtype of Crohn's disease, for example, a fibrostenotic subtype, a subtype characterized by the need for small bowel surgery, or a subtype characterized by the absence of features of ulcerative colitis.
Owner:CEDARS SINAI MEDICAL CENT
"Pharmaceutical Composition Comprising Stem Cells Treated with NOD2 Agonist or Culture Thereof for Prevention and Treatment of Immune Disorders and Inflammatory Diseases"
The present invention relates to a pharmaceutical composition for the prevention or treatment of immune disorders and inflammatory diseases, comprising stem cells that are generated by culturing stem cells expression Nucleotide-binding Oligomerization Domain protein 2 (NOD2) with a NOD2 agonist or a culture thereof. More particularly, the present invention relates to a method for suppressing immune responses or inflammatory responses of a subject, comprising the step of administering the pharmaceutical composition, the stem cells or culture thereof to the subject, a method for preparing an immunosuppressive drug or an anti-inflammatory drug using the stem cells or culture thereof, a method for preparing PGE2 or TGF-β1 comprising the step of culturing NOD2-expressing stem cells in culture medium with a NOD2 agonist, a graft comprising stem cells expressing NOD2 and the NOD2 agonist, a method for preparing the graft, a composite comprising stem cells expressing NOD2 and the NOD2 agonist, and a culture generated by culturing the NOD2-expressing stem cells with a NOD2 agonist.
Owner:KANGSTEM BIOTECH
Use of toll-like receptor-9 agonists
The present invention relates to the use of a TLR9 agonist and / or a TLR4 antagonist and / or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.
Owner:UNIVERSITY OF PITTSBURGH
Use of Toll-like receptor-9 agonists, Toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of Toll-like receptor-4-associated disorders
ActiveUS20120077868A1Reduce marksReduce signalingAntibacterial agentsBiocideDiseaseNK1 receptor antagonist
The present invention relates to the use of a TLR9 agonist and / or a TLR4 antagonist and / or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.
Owner:UNIVERSITY OF PITTSBURGH
Modulators on Nod2 signaling
Owner:RGT UNIV OF MICHIGAN
Modulators on Nod2 signaling
The present invention relates to intracellular signaling molecules, in particular the Nod2 protein and nucleic acids encoding the Nod2 protein. The present invention provides methods of identifying modulators of Nod2 signaling. In particular, the present invention additionally provides methods of screening immune modulators such as adjuvants using Nod2. The present invention further provides methods of altering Nod2 signaling.
Owner:RGT UNIV OF MICHIGAN
Method for screening compounds for treating sepsis targeting nod2 signalling pathway and composition for treating sepsis comprising nod2 signalling pathway inhibitors
Methods for screening compounds for treating sepsis are disclosed. The present methods and compositions are targeting NOD2 mediated signaling pathway and the agents identified by the present methods are qualified as drug candidates for clinical development. Further Methods and composition for treating sepsis are disclosed.
Owner:SEOUL NAT UNIV R&DB FOUND
Bioactive molecules produced by probiotic bacteria and methods for isolating and using the same
InactiveUS20160024149A1Inhibition of replicationReduce expressionBiocideOrganic active ingredientsLactobacillus rhamnosusImmunodeficiency virus
The present invention is a method for isolating bioactive molecules secreted by probiotic bacteria such as Lactobacillus rhamnosus, and methods for using such bioactive molecules to activate NOD2, decrease expression of inflammatory molecules, inhibit replication of human immunodeficiency virus (HIV), stimulate expression of Apolipoprotein A-IV, modulate diet-associated weight gain and prevent mucosal transmission of HIV.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
Diagnosis and treatment of inflammatory bowel disease
ActiveUS20150259748A1Great susceptibilityReduce in quantityMicrobiological testing/measurementLibrary screeningUlcerative colitisCvd risk
This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and / or subtypes of Crohn's disease (CD) and / or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and / or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and / or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and / or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and / or treatment of IBD, including CD and / or UC.
Owner:CEDARS SINAI MEDICAL CENT
Chimeric Phage Tail Proteins and Uses Thereof
InactiveUS20110021414A1Reduce bacteria countAntibacterial agentsBiocideBactericidal/permeability-increasing proteinBinding domain
A multi-protein pyocin-like structure derived from a bacteriophage or a bacteriocin that includes a chimeric tail fiber having a protein receptor binding domain capable of recognizing Lipid A. A multiprotein pyocin-like structure, derived from a bacteriophage or a bacteriocin that includes a chimeric tail fiber capable of recognizing and binding MurNac-L-Ala-D-Glu. A phage including a chimeric tail fiber that binds Lipid A. A plasmid encoding a chimeric ail fiber that binds MurNac-L-Ala-D-Glu. A plasmid encoding a chimeric tail fiber that binds Lipid A. A chimeric bacteriocin or bacteriophage derived tail fiber that includes the amino terminal of the human bactericidal / permeability-increasing protein (BPINTD)—A chimeric bacteriophage or bacteriocin derived tail fiber also includes a binding domain encoding the mammalian Nod2cτD—An antibacterial agent includes a bacteriocidal / permeability-increasing protein receptor domain that binds to Lipid A. An antibacterial agent also includes Nod2 carboxyl-terminus receptor domain that binds MurNac-L-Ala-D-Glu.
Owner:TEXAS A&M UNIVERSITY
Methods of using a nod2/card15 haplotype to diagnose crohn's disease
The present invention provides a method of diagnosing or predicting susceptibility to Crohn's disease in an individual by determining the presence or absence in the individual of a disease-predisposing haplotype containing a JW1 variant allele at the NOD2 / CARD15 locus, where the presence of the disease-predisposing haplotype is diagnostic of or predictive of susceptibility to Crohn's disease.
Owner:CEDARS SINAI MEDICAL CENT
Pharmaceutical composition comprising stem cells treated with NOD2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases
The present invention relates to a pharmaceutical composition for the prevention or treatment of immune disorders and inflammatory diseases, comprising stem cells that are generated by culturing stem cells expression Nucleotide-binding Oligomerization Domain protein 2 (NOD2) with a NOD2 agonist or a culture thereof. More particularly, the present invention relates to a method for suppressing immune responses or inflammatory responses of a subject, comprising the step of administering the pharmaceutical composition, the stem cells or culture thereof to the subject, a method for preparing an immunosuppressive drug or an anti-inflammatory drug using the stem cells or culture thereof, a method for preparing PGE2 or TGF-β1 comprising the step of culturing NOD2-expressing stem cells in culture medium with a NOD2 agonist, a graft comprising stem cells expressing NOD2 and the NOD2 agonist, a method for preparing the graft, a composite comprising stem cells expressing NOD2 and the NOD2 agonist, and a culture generated by culturing the NOD2-expressing stem cells with a NOD2 agonist.
Owner:KANGSTEM BIOTECH
Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and / or subtypes of Crohn's disease (CD) and / or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and / or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and / or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and / or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and / or treatment of IBD, including CD and / or UC.
Owner:CEDARS SINAI MEDICAL CENT
Nod2 nucleic acids and proteins
InactiveUS20020127673A1Change activityIncreased riskBacteriaFermentationIntracellular signallingNucleotide
The present invention relates to intracellular signalling molecules, in particular the Nod2 protein and nucleic acids encoding the Nod2 protein. The present invention provides isolated nucleotide sequence encoding Nod2, isolated Nod2 peptides, antibodies that specifically bind Nod2, methods for the detection of Nod2, and methods for screening compounds for the ability to alter Nod2 associated signal transduction.
Owner:RGT UNIV OF MICHIGAN
Immunomodulation therapies for cancer
InactiveUS20190008918A1High activityImprove anti-cancer effectOrganic active ingredientsInorganic non-active ingredientsImmunotherapeutic agentImmunomodulations
The present disclosure provides a novel combination of a NOD2 agonist with an immunotherapeutic agent for the treatment of cancer. The disclosure also comprises methods of treatments wherein a pharmaceutical composition of NOD2 agonist is used in combination with an immunotherapeutic agent. A pharmaceutical composition comprises of NOD2 agonist and an immunotherapeutic agent comprising PD-1 axis antagonist or CTLA4 antagonist with a pharmaceutically acceptable diluent or carrier.
Owner:BIOXCEL LLC
Method for determining reduced predisposition to cancer based on genetic profile
The invention provide methods for early detection of a reduced risk of developing cancer, which comprises detecting the absence of a series of genetic polymorphisms associated with a predisposition of developing cancer, including the polymorphisms of the genes BRCA1, BRCA2, CARD15 (NOD2), CHEK2, CDKN2A (P16), CYP1B1, FGFR2 (KGFR2), MAP3K1 (MEKK1), p53 (TP53), TNRC9, XPD (ERCC2) and the genetic marker Rs6983267, in a biological sample from the analyzed subject, wherein the absence of the genetic polymorphisms is indicative of significantly decreased risk of developing, at least, breast cancer.
Owner:POMORSKA ACAD MEDYCZNA
Pharmaceutical Composition Comprising Stem Cells Treated with NOD2 Agonist or Culture Thereof for Prevention and Treatment of Immune Disorders and Inflammatory Diseases
PendingUS20170007668A1Pharmaceutical delivery mechanismSaccharide peptide ingredientsImmunosuppressive drugNucleotide
The present invention relates to a pharmaceutical composition for the prevention or treatment of immune disorders and inflammatory diseases, comprising stem cells that are generated by culturing stem cells expressing Nucleotide-binding Oligomerization Domain protein 2 (NOD2) or a culture thereof. More particularly, the present invention relates to a method for suppressing immune responses or inflammatory responses of a subject, comprising the step of administering the pharmaceutical composition, the stem cells or culture thereof to the subject, a method for preparing an immunosuppressive drug or an anti-inflammatory drug using the stem cells or culture thereof, a graft comprising stem cells expressing NOD2, a method for preparing the graft, a composite comprising stem cells expressing NOD2, and a culture generated by culturing the NOD2-expressing stem cells.
Owner:KANGSTEM BIOTECH
Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer?s disease
Disclosed is a new treatment for reducing amyloid beta (Aβ), for treating Alzheimer's disease (AD), for improvement of cognitive disorder or learning and memory disorder associated with AD and for the treatment of multiple sclerosis. It was found that a NOD2 agonist could improve phagocytosis of Aβ across the blood brain barrier, to be scavenged by increased concentration of patrolling monocytes caused by the NOD2 agonist, removing Aβ from circulation, thereby preventing its eventual deposit. Also disclosed is a composition for such use.
Owner:UNIV LAVAL
Synthetic n-acetyl-muramic acid derivatives and uses thereof
ActiveUS20180298061A1Stabilizing NodModulating innate immune responseEsterified saccharide compoundsBacterial antigen ingredientsDipeptideFluorescence
The present invention provides N-acetyl-muramic acid (NAM) derivatives having Formula I, wherein Xa is selected from the group consisting of X1-X59, Ya is selected from the group consisting of H, monophosphate, uridine diphosphate and ethyl azide linker prepared from 2-azido-ethanol, and Za is selected from the group consisting of OH, an ethylene diamine coupled fluorophore, a peptide and a peptide with an ethylene diamine coupled fluorophore, wherein the peptide is selected from the group consisting of a monopeptide, a dipeptide, a tripeptide and a pentapeptide. Also provided are methods for synthesizing NAM derivatives and methods for modulating Nod2 in cells, modifying bacterial cell wall or modulating innate immune response by a subject to bacterial cells upon exposure to NAM derivatives.
Owner:UNIVERSITY OF DELAWARE
Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
PendingUS20220033486A1Peptide/protein ingredientsImmunoglobulins against cytokines/lymphokines/interferonsBronchial mucusBronchial epithelium
Bronchial remodelling is a prominent feature of severe asthma and a potential therapeutic target. Some data indicate that Th17 cytokines in particular IL-22 may be involved in remodelling processes in vitro, and in skin remodelling in vivo. The aim of the inventors was to evaluate if Th17 cytokines are involved in bronchial remodelling in a severe model of allergic asthma, and if this was amplified by co-sensitization with NOD2 agonist, MDP, a ligand favouring Th17 polarization. Dog allergen challenge led to a predominant neutrophilic infiltration in Broncho-alveolar lavage (BAL), increased dog-specific IgE production, airways hyperresponsiveness, and increased Th17 cytokine production. Increased bronchial remodeling was observed in dog allergen challenged mice compared to control. IL-22 deficiency decreased airway hyperresponsiveness, bronchial mucus production as well as peribronchial collagen deposition, in the allergen-challenged group. Th17 cytokines in particular IL-22 participate in the bronchial remodeling in a chronic model of neutrophilic asthma, and may represent a therapeutic target in severe asthma.
Owner:INSERM INST NAT SANTE RECH MEDICALE +4
Synthetic N-acetyl-muramic acid derivatives and uses thereof
The present invention provides N-acetyl-muramic acid (NAM) derivatives having Formula I, wherein Xa is selected from the group consisting of X1-X59, Ya is selected from the group consisting of H, monophosphate, uridine diphosphate and ethyl azide linker prepared from 2-azido-ethanol, and Za is selected from the group consisting of OH, an ethylene diamine coupled fluorophore, a peptide and a peptide with an ethylene diamine coupled fluorophore, wherein the peptide is selected from the group consisting of a monopeptide, a dipeptide, a tripeptide and a pentapeptide. Also provided are methods for synthesizing NAM derivatives and methods for modulating Nod2 in cells, modifying bacterial cell wall or modulating innate immune response by a subject to bacterial cells upon exposure to NAM derivatives.
Owner:UNIVERSITY OF DELAWARE
Diagnosis and treatment of inflammatory bowel disease
This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and / or subtypes of Crohn's disease (CD) and / or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and / or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and / or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and / or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and / or treatment of IBD, including CD and / or UC.
Owner:CEDARS SINAI MEDICAL CENT
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com